| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026 |
| 13 Nov 2026 | 10-Q |
| 12 Nov 2026 |
Form 4: Wise John Drayton, Director
Granted 17,000 Director Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Valentine James Elwood, Director
Granted 17,000 Director Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Patterson Leone D, Director
Granted 17,000 Director Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Bonuccelli Catherine M., Director
Granted 17,000 Director Stock Option (Right to Buy) |
| 12 Nov 2026 |
Form 4: Militello John, Chief Financial Officer
Received 80,000 shares as a grant or award |
| 05 Nov 2026 | 144 |
| 21 Oct 2026 | 144 |
| 19 Oct 2026 |
Form 3: Bonuccelli Catherine M., Director
No securities owned |
| 19 Oct 2026 |
Form 3: Valentine James Elwood, Director
No securities owned |
| 19 Oct 2026 |
Form 3: Wise John Drayton, Director
No securities owned |
| 19 Oct 2026 |
Form 3: Militello John, Chief Financial Officer
No securities owned |
| 19 Oct 2026 | Form 3: Fandrick Keith R., Chief Operating Officer |
| 19 Oct 2026 |
Form 3: Patterson Leone D, Director
No securities owned |
Loading...